Hospira HSP

  1. All
  2. Commentary
  3. Headlines
    1. Fresenius, buyout groups eye Danone Medical Nutrition unit - sources

      Headlines

      Fri, 17 Oct 2014

      healthcare group Fresenius as well as buyout groups PAI and Permira are exploring an acquisition of the medical nutrition business of Danone after efforts of U.S. drugmaker Hospira to buy the unit failed, people familiar with the matter said.

    2. Hospira may cut sales staff after losing Precedex case

      Headlines

      Mon, 8 Sep 2014

      rules that sales of generic versions of Hospira 's ( HSP -2.1% ) proprietary sedative ..... introduction of generic formulations. Hospira has filed an appeal of the decision and ..... version. Despite the adverse ruling, Hospira reaffirms its 2014 EPS guidance of $2

    3. CareFusion Ends Fiscal Year on Strong Note as Outlook Matches Our Expectations

      Commentary

      Fri, 8 Aug 2014

      infusion pump sales surging 40%; the company should continue to benefit from ongoing market share gains as competitors like Hospira struggle with regulatory issues. The company has also made progress in the installation of its Pyxis ES system, which led

    4. Hospira Posts Strong Results as Injectable Manufacturing Issues Improve

      Commentary

      Wed, 30 Jul 2014

      plan to raise our fair value estimate for Hospira after the company reported strong second ..... product. We don’t plan any changes to Hospira ’s narrow economic moat, but the recent ..... Asia more than offset negative pricing on Hospira ’s European injectables. Management reported

    5. Axiron Sales Back on Track; New Acrux CEO announced: Fair Value Unchanged

      Commentary

      Thu, 24 Jul 2014

      Netherlands and brings 25 years of experience in the global pharmaceutical industry, which includes senior management roles in Hospira and Mayne Group. Our fair value estimate of AUD 2.50 per share and investment thesis remain intact pending the release of

    6. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      BBB- 2020 5.50% $108.88 3.73% 188 Hospira HSP BBB- 2023 5.80% $111.56 4.26 ..... 50 basis points of additional tightening. Hospira HSP "> HSP (rating: BBB-, narrow moat) Hospira 's bonds could outperform its peers, as

    7. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers

      Headlines

      Tue, 3 Jun 2014

      this quarter: three that worked out well (Cimarex Energy, Concho Resources and Crane) and three that didn’t (Encana, Hospira and Quest Diagnostics)... In the case of Encana and Quest Diagnostics, fundamental underperformance caused us to reexamine

    8. Hospira Posts Encouraging First-Quarter Results, but Generic Precedex Should Slow Momentum

      Commentary

      Wed, 30 Apr 2014

      Hospira posted first-quarter results that slightly ..... allowances during last year's device issues, Hospira realized 7.5% revenue growth when excluding ..... to shift our $44 fair value estimate as Hospira continues to face considerable challenges

    9. Hospira HSP Q1 2014 Earnings Call Transcript

      Headlines

      Wed, 30 Apr 2014

      Welcome to Hospira 's First Quarter 2014 Conference Call ..... conference call and webcast discussing Hospira 's financial results for the first quarter ..... Mike Ball, Chief Executive Officer of Hospira and Tom Werner, Senior Vice President

    10. Oakmark Equity and Income Fund Letter to Shareholders

      Headlines

      Tue, 8 Apr 2014

      establish a meaningful position. Hospira was a longtime holding of the Fund ..... Laboratories, which spun-off Hospira ten years ago. Over the past few years ..... Crane Co. 0%, Encana Corp. 0%, Hospira , Inc . 0%, Abbott Laboratories 0

    « Prev12345Next »
    Content Partners